ArticleRespiratory medicine case reports2024
Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib.
Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L861Q often resulted in a lack of response to the first and third generation of EGFR TKIs. In this study, we reported a 64-year-old female patient, who initially presented with symptoms of pneumonia and showed positive response to anti-infection treatment, eventually diagnosed with stage Ⅳ lung adenocarcinoma (LUAD) harboring a rare EGFR G719X and L861Q compound mutations. The patient received 40 mg/day of afatinib and experienced no severe adverse events. As a result, partial response (PR) was observed based on CT scan and a progression free survival of 24 month was achieved. Her follow-up is still ongoing. The results of the present case support the effectiveness and safety of afatinib in LUAD patients carrying EGFR G719X and L861Q compound mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.